Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies.
Times cited: 146
Complications of multiple myeloma therapy, part 2: Risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia.
JNCCN Journal of the National Comprehensive Cancer Network.
Times cited: 15